Journal
DIABETES & VASCULAR DISEASE RESEARCH
Volume 9, Issue 4, Pages 256-269Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164112440816
Keywords
Incretin; GLP-1; DPP-4 inhibitor; ischaemia-reperfusion injury; heart
Funding
- Thailand Research Fund Royal Golden Jubilee PhD Project
- Thailand Research Fund [RTA5280007, BRG5480003]
Ask authors/readers for more resources
Incretin is a gut derived peptide hormone secreted in the intestine after food ingestion, and is degraded rapidly after secretion by dipeptidyl peptidase (DPP)-4. Incretin-based therapy, such as glucagon-like peptide (GLP)-1 and the DPP-4 inhibitor, has been proposed as a new therapeutic approach for the treatment of type 2 diabetic patients. In the past few years, growing evidence also demonstrated the cardioprotective effects of incretin-based therapy, especially during ischaemia-reperfusion (I/R) injury in both the animal models and in clinical studies. However, inconsistent reports exist regarding the use of these pharmacological interventions. In this article, a comprehensive review regarding both basic and clinical studies reporting the effects of GLP-1 and DPP-4 inhibitors on I/R hearts is presented and discussed. The consistent findings as well as controversial results are summarised, focusing on the effects of incretin on the infarct size, left ventricular function and haemodynannic improvement during an I/R injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available